Drugs.com - New Drug Approvals

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease...

Feb 9, 2025 - 22:25
 0
FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease...
Read More

Tags:

Previous Article

FDA Approves Lumakras (sotorasib) in Combination with Vectibix (panitumumab) for...

Next Article

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of N...

Related Posts

FDA Approves Alhemo (concizumab-mtci) to Prevent or Reduce Bleeding Episodes in People with Hemophilia A or B with Inhibitors

FDA Approves Alhemo (concizumab-mtci) to Prevent or Red...

Feb 9, 2025  0

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatm...

Feb 9, 2025  0

FDA Approves Crenessity (crinecerfont) for the Treatment of Children and Adults with Classic Congenital Adrenal Hyperplasia

FDA Approves Crenessity (crinecerfont) for the Treatmen...

Feb 9, 2025  0